MERCK & CO INCMM

MERCK & CO INC

1,789.21MXND
+6.21+0.35%
At close at Mar 28, 17:05 GMT
MXN
No trades
See on Supercharts

MRK fundamentals

Key facts

Market capitalization‪4.58 T‬MXN
Founded1891
Employees (FY)‪75 K‬
CEORobert M. Davis
Websitemerck.com
About

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Ownership
‪‪2.53 B‬‬
Free Float shares
‪‪2.52 B‬‬ (99.91%)
Closely held shares
‪‪2.30 M‬‬ (0.09%)
Free Float shares
‪‪2.52 B‬‬ (99.91%)
Closely held shares
‪‪2.30 M‬‬ (0.09%)
Capital structure
Market cap
‪‪4.58 T‬‬
Debt
‪‪797.91 B‬‬
Minority interest
‪‪1.23 B‬‬
Cash & equivalents
‪‪286.99 B‬‬
Enterprise value
‪‪5.09 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪4.58 T‬‬
Price to earning ratio (P/E)
13.83x
Price to sales ratio (P/S)
3.48x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
13.83x
Price to sales ratio (P/S)
3.48x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪210.00‬
‪420.00‬
‪630.00‬
‪840.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−12%‬
‪0%‬
‪12%‬
‪24%‬
‪36%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−110.00 B‬‬
‪0.00‬
‪‪110.00 B‬‬
‪‪220.00 B‬‬
‪‪330.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪80.00 B‬‬
‪‪160.00 B‬‬
‪‪240.00 B‬‬
‪‪320.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪80.00 B‬‬
‪‪160.00 B‬‬
‪‪240.00 B‬‬
‪‪320.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceutical
Animal Health
Other
By country
Period: 2024
United States
Europe, Middle East and Africa
China
Latin America
Japan
Asia Pacific
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪90.00 B‬‬
‪‪180.00 B‬‬
‪‪270.00 B‬‬
‪‪360.00 B‬‬
Actual
Estimate
Earnings
Next:Apr 24, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪11.00‬
‪22.00‬
‪33.00‬
‪44.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
46.33%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
3.50%
Last payment
16.175
Last ex-date
Mar 17, 2025
Dividend history
‪2.50%‬
‪2.75%‬
‪3.00%‬
‪3.25%‬
‪3.50%‬
2020
2021
2022
2023
2024
‪0.00‬
‪17.00‬
‪34.00‬
‪51.00‬
‪68.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−300.00 B‬‬
‪0.00‬
‪‪300.00 B‬‬
‪‪600.00 B‬‬
‪‪900.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪450.00 B‬‬
‪‪900.00 B‬‬
‪‪1.35 T‬‬
‪‪1.80 T‬‬
Assets
Liabilities